SARS-CoV-2 Subunit Virus-Like Vaccine Demonstrates High Safety Profile and Protective Efficacy: Preclinical Study
A. V. Vakhrusheva, A. V. Kudriavtsev, N. A. Kryuchkov, R. V. Deev, M. E. Frolova, K. A. Blagodatskikh, M. Djonovic, A. A. Nedorubov, E. Odintsova, A. V. Ivanov, E. A. Romanovskaya-Romanko, M. A. Stukova, A. A. Isaev, I. V. Krasilnikov
This paper evaluates a subunit vaccine, Betuvax-CoV-2, showing high safety and protective efficacy in preclinical models, leading to ongoing clinical trials.
bioRxiv · May 18, 2022 · PreprintPharmacology & Toxicology